Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target

Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.

BenzingaJun 18 13:48 ET

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $80 to $100

On Jun 18, major Wall Street analysts update their ratings for $Keros Therapeutics(KROS.US)$, with price targets ranging from $80 to $100.BofA Securities analyst Jason Zemansky initiates coverage with

moomoo NewsJun 18 09:00 ET · Ratings

Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair

Keros Therapeutics (KROS) said late Monday that Chief Executive Officer Jasbir Seehra will take over as board chair from July 1. The company said Carl Gordon, the current chair, will remain an "active

MT NewswiresJun 18 05:23 ET

Express News | Keros Therapeutics:Filed Prospectus Supplement to Co's Shelf Registration Statement for Issuance & Sale of up to $350 Mln Shares of Common Stock

ReutersJun 17 17:23 ET

Express News | Keros Therapeutics Appointed Jasbir S. Seehra Chief Executive Officer, Chair Of The Board, Effective July 1, 2024; Christopher Rovaldi Promoted To President, Effective July 1, 2024

BenzingaJun 17 16:08 ET

Keros Therapeutics Rovaldi Will Also Continue Serving as Oper Chief >KROS

Keros Therapeutics Rovaldi Will Also Continue Serving as Oper Chief >KROS

Dow JonesJun 17 16:02 ET